Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk

Molecular Biology Reports

Volumn 40, Issue 3, 2013, Pages 2389-2395

  Liu, Zhi Hong ^a   Bao, Er Dun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Meta analysis; Polymorphism; TP53 Arg72Pro

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; EAST ASIAN; ETHNIC GROUP; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PROTEIN POLYMORPHISM; QUANTITATIVE ANALYSIS;

AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RISK; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84878405187     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2319-z     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239-249
3. Taioli E, Raimondi S (2005) Genetic susceptibility to bladder cancer. Lancet 366:610-612
4. Chipuk JE, Bouchier-Hayes L, Kuwana T et al (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309:1732-1735
5. Riley T, Sontag E, Chen P et al (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412
6. Dumont P, Leu JI, Della Pietra AC III et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365
7. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107
8. Mabrouk I, Baccouche S, El-Abed R et al (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764-770
9. Ye Y, Yang H, Grossman HB et al (2008) Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112:2467-2474
10. Srivastava P, Jaiswal PK, Singh V et al (2010) Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark 8:21-28
11. Pandith AA, Shah ZA, Khan NP et al (2010) Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet 203:263-268
12. Kuroda Y, Tsukino H, Nakao H et al (2003) p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 189:77-83
13. Soulitzis N, Sourvinos G, Dokianakis DN et al (2002) p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179:175-183
14. Zhang R, Chen W, Zhang W et al (2011) Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospital-based case-control study. Genet Test Mol Biomarkers 15:337-341
15. Wu WJ, Kakehi Y, Habuchi T et al (1995) Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res 86:730-736
16. Biros E, Kalina I, Salagovic J et al (2000) p53 single nucleotide polymorphisms and bladder cancer. Neoplasma 47:303-306
17. Horikawa Y, Nadaoka J, Saito M et al (2008) Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep 20:49-55
18. Lin HY, Huang CH, Yu TJ et al (2012) p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep 27:1193-1199
19. Chung CJ, Huang CJ, Pu YS et al (2008) Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol 232:203-209
20. Lin HY, Huang CH, Yu TJ et al (2011) p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in a Taiwanese population: an implication of structural equation modeling to manage the risks of bladder cancer. Urol Int 86:355-360
21. Santos LE, Guilhen AC, de Andrade RA et al (2011) The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol Oncol 29:291-294
22. Chen WC, Tsai FJ, Wu JY et al (2000) Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 28:293-296
23. Toruner GA, Ucar A, Tez M et al (2001) P53 codon 72 polymorphism in bladder cancer-no evidence of association with increased risk or invasiveness. Urol Res 29:393-395
24. Attia J, Thakkinstian A, D'Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297-303
25. Salanti G, Amountza G, Ntzani EE et al (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13:840-848
26. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM et al (2003) Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 34:1634-1639
27. Zintzaras E, Raman G, Kitsios G et al (2008) Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. Arch Intern Med 168:1077-1089
28. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
30. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
31. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129
32. Thompson SG, Higgins J (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573
33. Burchard EG, Ziv E, Coyle N et al (2003) The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348:1170-1175
34. Bhopal R (2004) Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 58:441-445
35. Stuck AE, Rubenstein LZ, Wieland D (1998) Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ 316:469
36. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
37. Chen YC, Xu L, Guo YL et al (2004) Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers 9:386-394
38. Gao W, Romkes M, Zhong S et al (2010) Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep 24:257-262
39. Jiang DK, Ren WH, Yao L et al (2010) Meta-analysis of association between TP53 Arg72Pro polymorphism and bladder cancer risk. Urology 76(765):e761-e767
40. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283
41. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914-916